Li Luchi, Anjani Qonita Kurnia, Hutton Aaron R J, Li Mingshan, Sabri Akmal Hidayat Bin, Vora Lalitkumar, Naser Yara A, Tao Yushi, McCarthy Helen O, Donnelly Ryan F
School of Pharmacy, Medical Biology Centre, Queens University Belfast, 97 Lisburn Road, BT9 7BL, Belfast, United Kingdom.
School of Pharmacy and Pharmaceutical Sciences, Ulster University, Coleraine, United Kingdom, Block Y, 1SA, Cromore Rd, BT52 1SA.
Drug Deliv Transl Res. 2024 Nov 20. doi: 10.1007/s13346-024-01737-0.
Hydrogel-forming microneedle (MN) arrays are minimally-invasive devices that can penetrate the stratum corneum, the main barrier to topical drug application, without causing pain. However, drug delivery using hydrogel-forming MN arrays tends to be relatively slow compared to rapid drug delivery using conventional needles and syringes. Therefore, in this work, for the first time, different physical and chemical delivery enhancement methods were employed in combination with PVA-based hydrogel-forming MN arrays. Using a model drug, ibuprofen (IBU) sodium, the designed systems were assessed in terms of the extent of transdermal delivery. Iontophoresis (ITP) and heat-assisted drug delivery technology were investigated as physical permeation enhancement techniques. Ex vivo studies demonstrated that the ITP (0.5 mA/cm)-mediated combination strategy significantly enhanced the transdermal permeation of IBU sodium over the first 6 h (~ 5.11 mg) when compared to MN alone (~ 1.63 mg) (p < 0.05). In contrast, heat-assisted technology showed almost no promoting effect on transdermal delivery. Furthermore, IBU sodium-containing rapidly dissolving lyophilised and effervescent reservoirs, classified as chemical modification methods, were prepared. Both strategies achieved rapid and effective ex vivo IBU sodium permeation, equating to ~ 78% (30.66 mg) and ~ 71% (28.43 mg) from lyophilised and effervescent reservoirs, respectively. Moreover, in vivo pharmacokinetic studies showed that the IBU sodium plasma concentration within lyophilised and effervescent groups reached a maximum concentration (C) at 4 h (~ 282.15 µg/mL) and 6 h (~ 140.81 µg/mL), respectively. These strategies not only provided rapid achievement of therapeutic levels (10-15 µg/ml), but also resulted in sustained release of IBU sodium for at least 48 h, which could effectively reduce the frequency of administration, thereby improving patient compliance and reducing side effects of IBU sodium.
形成水凝胶的微针(MN)阵列是一种微创设备,它可以穿透角质层(局部给药的主要屏障)且不会引起疼痛。然而,与使用传统针头和注射器的快速给药相比,使用形成水凝胶的MN阵列进行药物递送往往相对较慢。因此,在这项工作中,首次将不同的物理和化学递送增强方法与基于聚乙烯醇(PVA)的形成水凝胶的MN阵列结合使用。使用模型药物布洛芬(IBU)钠,根据透皮递送程度对设计的系统进行评估。研究了离子电渗疗法(ITP)和热辅助药物递送技术作为物理渗透增强技术。体外研究表明,与单独使用MN(1.63mg)相比,ITP(0.5mA/cm)介导的联合策略在最初6小时内显著增强了IBU钠的透皮渗透(5.11mg)(p<0.05)。相比之下,热辅助技术对透皮递送几乎没有促进作用。此外,制备了含IBU钠的快速溶解冻干和泡腾储库,归类为化学修饰方法。两种策略均实现了快速有效的体外IBU钠渗透,分别相当于冻干储库和泡腾储库的78%(30.66mg)和71%(28.43mg)。此外,体内药代动力学研究表明,冻干组和泡腾组的IBU钠血浆浓度分别在4小时(282.15μg/mL)和6小时(140.81μg/mL)达到最大浓度(C)。这些策略不仅能快速达到治疗水平(10 - 15μg/ml),还能使IBU钠持续释放至少48小时,这可以有效减少给药频率,从而提高患者依从性并减少IBU钠的副作用。